Alsma, Jelmer

Baan, J. (Janneke)

Bos, Monique MEM

Gonesh-Kisoensingh, Savita U

Meijer, Erik

Meynaar, IA (Iwan)

Vulto, Arnold G

English

Background: The use of capecitabine has risen exponentially in the Netherlands since 2001. Clinical trialsdescribe a mild toxicity profile. Because circumstances in daily clinical practice can differ a lot from clinical trialsetting, we performed this retrospective analysis in a large community hospital to verify toxicity in a clinical situation.Methods: A retrospective cohort study was conducted in patients with malignancies of the gastrointestinal tractor breast treated with capecitabine in the period of January 2007 to January 2009. Primary study endpoint was theincidence and severity of capecitabine-induced toxicity in daily clinical practice. Secondary endpoint concerneddetermination of risk factors for toxicity due to capecitabine.Results: Of 281 patients 92% experienced some degree of toxicity. Grade 3-4 toxicity occurred in 30% ofpatients receiving monotherapy and in 47% with combination therapy. This was in accordance with the literature.Type of toxicity varied, but gastro intestinal symptoms and hand foot syndrome were most commonly found. Risk oftoxicity increased with increasing age, independently of creatinine clearance.Conclusions: Therapy with capecitabine monotherapy or capecitabine containing regiments in daily clinicalpractice is accompanied by considerable toxicity, but frequency and severity are consistent with published clinicaltrials. More toxicity can be expected with increasing age

EUR Research Repository

Capecitabine-induced Toxicity: An Outcome Study into Drug Safety

https://pure.eur.nl/files/53155709/capecitabine_induced_toxicity_an_outcome_study_into_drug_safety_2329_6771.1000113.pdf

Capecitabine-induced Toxicity: An Outcome Study into Drug Safety

Abstract

Similar works

Full text

Available Versions

EUR Research Repository

EUR Research Repository